TME Pharma N.V.

€0.11As of Sun 8 Nov 2026, 12:00 UTC
EPA:ALTMEHealthcare
Country France
PE (Fwd) •••
TSR 10Y CAGR (62.51%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.80
PE TTM —
TSR TTM 9.39%
Mkt cap €10.09M
ROIC (150.40%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
€0.123
14.51%
(97.54%)
Hold 5|9|7|9|3
4Q25
1Q26
2Q26
3Q26
Earnings per share€
—
—
—
—
8.13%
(7.95%)
4.50%
4.86%
Revenue€M
0.879
0.876
0.925
0.919
3.42%
(1.88%)
3.39%
3.35%
Peers (US$11.33M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
6.096
(0.025)
(0.028)
EBIT/Intx
0.247
5.119
4.288
Own earn%
(31.06)
(18.82)
(22.40)
Sh yield%
32.61
30.41
31.11
Owners
Insiders/Inst%
9.15
72.97
Short interest%
1.49
SBC / revenue%
4.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
0–6
$1 testx
−0.1
Incr. ROIC%
9